We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Bladder Cancer

Journal Scan / Research · November 04, 2020

Atezolizumab in Patients With Metastatic Urothelial Carcinoma Who Progressed After First-Line Chemotherapy

European Urology Focus

 

Additional Info

European Urology Focus
Atezolizumab in Patients With Metastatic Urothelial Carcinoma Who Have Progressed After First-Line Chemotherapy: Results of Real-Life Experiences
Eur Urol Focus 2020 Sep 30;[EPub Ahead of Print], D Tural, ÖF Ölmez, AT Sümbül, M Artaç, N Özhan, E Akar, B Çakar, O Köstek, M Ekenel, M Erman, HŞ Coşkun, F Selçukbiricik, Ö Keskin, FP Türköz, K Oruç, S Bayram, U Yılmaz, İ Bilgetekin, B Yıldız, MAN Şendur, N Paksoy, A Dirican, D Erdem, M Selam, Ö Tanrıverdi, S Paydaş, Z Urakçı, E Atağ, S Güncan, Y Ürün, A Alkan, AO Kaya, DT Özyükseler, H Taşkaynatan, M Yıldırım, M Sönmez, T Başoğlu, Ş Gündüz, S Kılıçkap

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading